Picture loading failed.

Anti-TNFRSF10B therapeutic antibody (Pre-made Drozitumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Drozitumab is a human monoclonal antibody in development for the treatment of cancers.[1] It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.[2] Drozitumab was developed by Genentech.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-156-1mg 1mg 3090
GMP-Bios-ab-156-10mg 10mg 21890
GMP-Bios-ab-156-100mg 100mg 148000
GMP-Bios-ab-156-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-TNFRSF10B therapeutic antibody (Pre-made Drozitumab biosimilar,Whole mAb)
INN Name Drozitumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure4od2:BA
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChondrosarcoma;Colorectal cancer;Non-Hodgkin's lymphoma;Non-small cell lung cancer
Development Techna